Login to Your Account

CureVac in $33M Research Deal on mRNA Vaccines

By Cormac Sheridan
BioWorld International Correspondent

Wednesday, November 16, 2011
CureVac GmbH entered a five-way, $33.1 million research collaboration to develop mRNA-based vaccines against undisclosed infectious disease pathogens, using its RNActive technology.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription